Preventing MDMA-Related Hyponatremia: The Role of Fluid Restriction in Safety

Preventing MDMA-Related Hyponatremia: The Role of Fluid Restriction in Safety

November 26, 2024 Catherine Williams - Chief Editor Health

TOPLINE:

Acute hyponatremia, a condition with low sodium levels in the blood, often occurs after a single dose of MDMA (ecstasy) in healthy individuals. This effect may stem from oxytocin rather than vasopressin and can be reduced by restricting fluid intake.

METHODOLOGY:

  • MDMA is being explored as a treatment for posttraumatic stress disorder (PTSD). However, even a single dose can cause acute hyponatremia.
  • Researchers conducted a secondary analysis of four randomized, placebo-controlled, double-blind, crossover clinical trials. They examined the incidence and severity of hyponatremia in healthy participants given 100 mg or 125 mg of MDMA.
  • Measurements included plasma oxytocin, copeptin, and sodium levels taken repeatedly within 360 minutes post-MDMA intake, peaking at 180 minutes.
  • The researchers assessed hyponatremia incidence and severity, the effect of fluid restriction on sodium levels, and MDMA’s impact on plasma oxytocin and copeptin levels.

TAKEAWAY:

  • A total of 96 participants (average age 29; 35% women) were involved. They received either 100 mg (41%) or 125 mg (59%) MDMA, with fluid intake restricted in 15 participants and unrestricted in 81.
  • Hyponatremia occurred in 31% of participants. A larger decrease in sodium levels was noted in individuals receiving higher doses (P = .045).
  • Fluid restriction provided significant protection. None in the restricted group experienced hyponatremia, compared to 37% in the unrestricted group (P = .002).
  • Plasma oxytocin levels rose by 433% at 180 minutes, while copeptin levels slightly decreased by 0.8 pmol/L.
  • Among participants with restricted fluid intake, plasma sodium changes negatively correlated with changes in oxytocin (R = -0.4; P < .01).

IN PRACTICE:

The study suggests restricting fluid intake when using MDMA in therapeutic settings, such as MDMA-assisted therapy for PTSD.

SOURCE:

The study, led by Cihan Atila, MD, PhD, from the University Hospital Basel, was published in JAMA Network Open.

LIMITATIONS:

The research had a small sample size in the fluid restriction group and an imbalance in sex distribution. Only single doses of MDMA were tested without a placebo assessment. Fluid intake and intravenous saline application were recorded only for patients on fluid restriction.

DISCLOSURES:

The study received a grant from the Swiss National Science Foundation and other financial support. Some authors reported research grants and consulting roles with various institutions and companies.

, , ,